Human	B:C0444008
Leucocyte	I:C0444008
Antigen	I:C0444008
B50	I:C0444008
Is	O
Associated	O
with	O
Conversion	O
to	O
Generalized	O
Myasthenia	I:C0751339
Gravis	I:C0751339
in	O
Patients	O
with	O
Pure	O
Ocular	I:C0751340
Onset	O
.	O

Human	O
Leucocyte	I:C0444008
Antigen	I:C0444008
B50	I:C0444008
Is	O
Associated	O
with	O
Conversion	O
to	O
Generalized	B:C0751339
Myasthenia	I:C0751339
Gravis	I:C0751339
in	O
Patients	O
with	O
Pure	O
Ocular	I:C0751340
Onset	O
.	O

Human	O
Leucocyte	I:C0444008
Antigen	I:C0444008
B50	I:C0444008
Is	O
Associated	O
with	O
Conversion	O
to	O
Generalized	O
Myasthenia	I:C0751339
Gravis	I:C0751339
in	O
Patients	O
with	O
Pure	B:C0751340
Ocular	I:C0751340
Onset	O
.	O

The	O
aim	O
of	O
this	O
study	B:C0008972
was	O
to	O
investigate	O
the	O
associations	O
between	O
major	O
histocompatibility	I:C0024518
complex	I:C0024518
(	O
major	O
histocompatibility	I:C0024518
complex	I:C0024518
)	O
class	O
I	I:C0017355
and	O
II	O
alleles	I:C0017349
and	O
disease	O
characteristics	O
in	O
Turkish	O
patients	O
with	O
myasthenia	O
gravis	I:C0026896
(	O
myasthenia	O
gravis	I:C0026896
)	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
associations	O
between	O
major	B:C0024518
histocompatibility	I:C0024518
complex	I:C0024518
(	O
major	O
histocompatibility	I:C0024518
complex	I:C0024518
)	O
class	O
I	I:C0017355
and	O
II	O
alleles	I:C0017349
and	O
disease	O
characteristics	O
in	O
Turkish	O
patients	O
with	O
myasthenia	O
gravis	I:C0026896
(	O
myasthenia	O
gravis	I:C0026896
)	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
associations	O
between	O
major	O
histocompatibility	I:C0024518
complex	I:C0024518
(	O
major	B:C0024518
histocompatibility	I:C0024518
complex	I:C0024518
)	O
class	O
I	I:C0017355
and	O
II	O
alleles	I:C0017349
and	O
disease	O
characteristics	O
in	O
Turkish	O
patients	O
with	O
myasthenia	O
gravis	I:C0026896
(	O
myasthenia	O
gravis	I:C0026896
)	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
associations	O
between	O
major	O
histocompatibility	I:C0024518
complex	I:C0024518
(	O
major	O
histocompatibility	I:C0024518
complex	I:C0024518
)	O
class	B:C0017355
I	I:C0017355
and	O
II	O
alleles	I:C0017349
and	O
disease	O
characteristics	O
in	O
Turkish	O
patients	O
with	O
myasthenia	O
gravis	I:C0026896
(	O
myasthenia	O
gravis	I:C0026896
)	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
associations	O
between	O
major	O
histocompatibility	I:C0024518
complex	I:C0024518
(	O
major	O
histocompatibility	I:C0024518
complex	I:C0024518
)	O
class	O
I	I:C0017355
and	O
II	B:C0017349
alleles	I:C0017349
and	O
disease	O
characteristics	O
in	O
Turkish	O
patients	O
with	O
myasthenia	O
gravis	I:C0026896
(	O
myasthenia	O
gravis	I:C0026896
)	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
associations	O
between	O
major	O
histocompatibility	I:C0024518
complex	I:C0024518
(	O
major	O
histocompatibility	I:C0024518
complex	I:C0024518
)	O
class	O
I	I:C0017355
and	O
II	O
alleles	I:C0017349
and	O
disease	O
characteristics	O
in	O
Turkish	B:C0549217
patients	O
with	O
myasthenia	O
gravis	I:C0026896
(	O
myasthenia	O
gravis	I:C0026896
)	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
associations	O
between	O
major	O
histocompatibility	I:C0024518
complex	I:C0024518
(	O
major	O
histocompatibility	I:C0024518
complex	I:C0024518
)	O
class	O
I	I:C0017355
and	O
II	O
alleles	I:C0017349
and	O
disease	O
characteristics	O
in	O
Turkish	O
patients	O
with	O
myasthenia	B:C0026896
gravis	I:C0026896
(	O
myasthenia	O
gravis	I:C0026896
)	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
associations	O
between	O
major	O
histocompatibility	I:C0024518
complex	I:C0024518
(	O
major	O
histocompatibility	I:C0024518
complex	I:C0024518
)	O
class	O
I	I:C0017355
and	O
II	O
alleles	I:C0017349
and	O
disease	O
characteristics	O
in	O
Turkish	O
patients	O
with	O
myasthenia	O
gravis	I:C0026896
(	O
myasthenia	B:C0026896
gravis	I:C0026896
)	O
.	O

The	O
major	B:C0024518
histocompatibility	I:C0024518
complex	I:C0024518
class	O
I	I:C0017355
and	O
II	O
alleles	I:C0017349
of	O
108	O
unrelated	O
myasthenia	O
gravis	I:C0026896
patients	O
were	O
genotyped	O
.	O

The	O
major	O
histocompatibility	I:C0024518
complex	I:C0024518
class	B:C0017355
I	I:C0017355
and	O
II	O
alleles	I:C0017349
of	O
108	O
unrelated	O
myasthenia	O
gravis	I:C0026896
patients	O
were	O
genotyped	O
.	O

The	O
major	O
histocompatibility	I:C0024518
complex	I:C0024518
class	O
I	I:C0017355
and	O
II	B:C0017349
alleles	I:C0017349
of	O
108	O
unrelated	O
myasthenia	O
gravis	I:C0026896
patients	O
were	O
genotyped	O
.	O

The	O
major	O
histocompatibility	I:C0024518
complex	I:C0024518
class	O
I	I:C0017355
and	O
II	O
alleles	I:C0017349
of	O
108	O
unrelated	O
myasthenia	B:C0026896
gravis	I:C0026896
patients	O
were	O
genotyped	O
.	O

The	O
major	O
histocompatibility	I:C0024518
complex	I:C0024518
class	O
I	I:C0017355
and	O
II	O
alleles	I:C0017349
of	O
108	O
unrelated	O
myasthenia	O
gravis	I:C0026896
patients	O
were	O
genotyped	B:C1285573
.	O

The	O
human	B:C0019721
leucocyte	I:C0019721
antigen	I:C0019721
(	O
human	O
leucocyte	I:C0019721
antigen	I:C0019721
)	O
distribution	O
of	O
all	O
myasthenia	O
gravis	I:C0026896
patients	O
and	O
subgroups	O
of	O
myasthenia	O
gravis	I:C0026896
patients	O
(	O
grouped	O
according	O
to	O
disease	O
characteristics	O
)	O
was	O
compared	O
to	O
that	O
of	O
250	O
healthy	O
controls	O
.	O

The	O
human	O
leucocyte	I:C0019721
antigen	I:C0019721
(	O
human	B:C0019721
leucocyte	I:C0019721
antigen	I:C0019721
)	O
distribution	O
of	O
all	O
myasthenia	O
gravis	I:C0026896
patients	O
and	O
subgroups	O
of	O
myasthenia	O
gravis	I:C0026896
patients	O
(	O
grouped	O
according	O
to	O
disease	O
characteristics	O
)	O
was	O
compared	O
to	O
that	O
of	O
250	O
healthy	O
controls	O
.	O

The	O
human	O
leucocyte	I:C0019721
antigen	I:C0019721
(	O
human	O
leucocyte	I:C0019721
antigen	I:C0019721
)	O
distribution	O
of	O
all	O
myasthenia	B:C0026896
gravis	I:C0026896
patients	O
and	O
subgroups	O
of	O
myasthenia	O
gravis	I:C0026896
patients	O
(	O
grouped	O
according	O
to	O
disease	O
characteristics	O
)	O
was	O
compared	O
to	O
that	O
of	O
250	O
healthy	O
controls	O
.	O

The	O
human	O
leucocyte	I:C0019721
antigen	I:C0019721
(	O
human	O
leucocyte	I:C0019721
antigen	I:C0019721
)	O
distribution	O
of	O
all	O
myasthenia	O
gravis	I:C0026896
patients	O
and	O
subgroups	B:C1515021
of	O
myasthenia	O
gravis	I:C0026896
patients	O
(	O
grouped	O
according	O
to	O
disease	O
characteristics	O
)	O
was	O
compared	O
to	O
that	O
of	O
250	O
healthy	O
controls	O
.	O

The	O
human	O
leucocyte	I:C0019721
antigen	I:C0019721
(	O
human	O
leucocyte	I:C0019721
antigen	I:C0019721
)	O
distribution	O
of	O
all	O
myasthenia	O
gravis	I:C0026896
patients	O
and	O
subgroups	O
of	O
myasthenia	B:C0026896
gravis	I:C0026896
patients	O
(	O
grouped	O
according	O
to	O
disease	O
characteristics	O
)	O
was	O
compared	O
to	O
that	O
of	O
250	O
healthy	O
controls	O
.	O

The	O
human	O
leucocyte	I:C0019721
antigen	I:C0019721
(	O
human	O
leucocyte	I:C0019721
antigen	I:C0019721
)	O
distribution	O
of	O
all	O
myasthenia	O
gravis	I:C0026896
patients	O
and	O
subgroups	O
of	O
myasthenia	O
gravis	I:C0026896
patients	O
(	O
grouped	B:C0439745
according	O
to	O
disease	O
characteristics	O
)	O
was	O
compared	O
to	O
that	O
of	O
250	O
healthy	O
controls	O
.	O

Overall	O
distributions	O
of	O
HLA	B:C0062847
-	I:C0062847
B	I:C0062847
*61	I:C0062847
and	O
C*05	O
were	O
more	O
frequent	O
in	O
myasthenia	O
gravis	I:C0026896
patients	O
(	O
7.4	O
vs.	O
2.0	O
%	O
and	O
14.8	O
vs.	O
6.8	O
%	O
,	O
respectively	O
)	O
than	O
in	O
non-MG	O
patients	O
.	O

Overall	O
distributions	O
of	O
HLA	O
-	I:C0062847
B	I:C0062847
*61	I:C0062847
and	O
C*05	B:C0062856
were	O
more	O
frequent	O
in	O
myasthenia	O
gravis	I:C0026896
patients	O
(	O
7.4	O
vs.	O
2.0	O
%	O
and	O
14.8	O
vs.	O
6.8	O
%	O
,	O
respectively	O
)	O
than	O
in	O
non-MG	O
patients	O
.	O

Overall	O
distributions	O
of	O
HLA	O
-	I:C0062847
B	I:C0062847
*61	I:C0062847
and	O
C*05	O
were	O
more	O
frequent	O
in	O
myasthenia	B:C0026896
gravis	I:C0026896
patients	O
(	O
7.4	O
vs.	O
2.0	O
%	O
and	O
14.8	O
vs.	O
6.8	O
%	O
,	O
respectively	O
)	O
than	O
in	O
non-MG	O
patients	O
.	O

Subgroup	B:C1515021
analyses	O
revealed	O
that	O
HLA	O
-	I:C0002085
DRB1	I:C0002085
*	I:C0002085
14	I:C0002085
and	O
DQB1*02	O
alleles	I:C0002085
were	O
more	O
frequent	O
in	O
early	O
-	I:C1833334
onset	I:C1833334
myasthenia	O
gravis	I:C0026896
[	O
n	O
=	O
10	O
(	O
20.8	O
%	O
)	O
vs.	O
n	O
=	O
25	O
(	O
10.0	O
%	O
)	O
and	O
n	O
=	O
21	O
(	O
43.8	O
%	O
)	O
vs.	O
n	O
=	O
59	O
(	O
23.6	O
%	O
)	O
]	O
.	O

Subgroup	O
analyses	B:C0936012
revealed	O
that	O
HLA	O
-	I:C0002085
DRB1	I:C0002085
*	I:C0002085
14	I:C0002085
and	O
DQB1*02	O
alleles	I:C0002085
were	O
more	O
frequent	O
in	O
early	O
-	I:C1833334
onset	I:C1833334
myasthenia	O
gravis	I:C0026896
[	O
n	O
=	O
10	O
(	O
20.8	O
%	O
)	O
vs.	O
n	O
=	O
25	O
(	O
10.0	O
%	O
)	O
and	O
n	O
=	O
21	O
(	O
43.8	O
%	O
)	O
vs.	O
n	O
=	O
59	O
(	O
23.6	O
%	O
)	O
]	O
.	O

Subgroup	O
analyses	O
revealed	O
that	O
HLA	B:C0002085
-	I:C0002085
DRB1	I:C0002085
*	I:C0002085
14	I:C0002085
and	O
DQB1*02	O
alleles	I:C0002085
were	O
more	O
frequent	O
in	O
early	O
-	I:C1833334
onset	I:C1833334
myasthenia	O
gravis	I:C0026896
[	O
n	O
=	O
10	O
(	O
20.8	O
%	O
)	O
vs.	O
n	O
=	O
25	O
(	O
10.0	O
%	O
)	O
and	O
n	O
=	O
21	O
(	O
43.8	O
%	O
)	O
vs.	O
n	O
=	O
59	O
(	O
23.6	O
%	O
)	O
]	O
.	O

Subgroup	O
analyses	O
revealed	O
that	O
HLA	O
-	I:C0002085
DRB1	I:C0002085
*	I:C0002085
14	I:C0002085
and	O
DQB1*02	B:C0002085
alleles	I:C0002085
were	O
more	O
frequent	O
in	O
early	O
-	I:C1833334
onset	I:C1833334
myasthenia	O
gravis	I:C0026896
[	O
n	O
=	O
10	O
(	O
20.8	O
%	O
)	O
vs.	O
n	O
=	O
25	O
(	O
10.0	O
%	O
)	O
and	O
n	O
=	O
21	O
(	O
43.8	O
%	O
)	O
vs.	O
n	O
=	O
59	O
(	O
23.6	O
%	O
)	O
]	O
.	O

Subgroup	O
analyses	O
revealed	O
that	O
HLA	O
-	I:C0002085
DRB1	I:C0002085
*	I:C0002085
14	I:C0002085
and	O
DQB1*02	O
alleles	I:C0002085
were	O
more	O
frequent	O
in	O
early	B:C1833334
-	I:C1833334
onset	I:C1833334
myasthenia	O
gravis	I:C0026896
[	O
n	O
=	O
10	O
(	O
20.8	O
%	O
)	O
vs.	O
n	O
=	O
25	O
(	O
10.0	O
%	O
)	O
and	O
n	O
=	O
21	O
(	O
43.8	O
%	O
)	O
vs.	O
n	O
=	O
59	O
(	O
23.6	O
%	O
)	O
]	O
.	O

Subgroup	O
analyses	O
revealed	O
that	O
HLA	O
-	I:C0002085
DRB1	I:C0002085
*	I:C0002085
14	I:C0002085
and	O
DQB1*02	O
alleles	I:C0002085
were	O
more	O
frequent	O
in	O
early	O
-	I:C1833334
onset	I:C1833334
myasthenia	B:C0026896
gravis	I:C0026896
[	O
n	O
=	O
10	O
(	O
20.8	O
%	O
)	O
vs.	O
n	O
=	O
25	O
(	O
10.0	O
%	O
)	O
and	O
n	O
=	O
21	O
(	O
43.8	O
%	O
)	O
vs.	O
n	O
=	O
59	O
(	O
23.6	O
%	O
)	O
]	O
.	O

In	O
patients	O
seropositive	O
for	O
anti-AchR	B:C0236516
antibodies	I:C0236516
,	O
the	O
frequencies	O
of	O
HLA	O
-	O
B*50	O
and	O
C*05	O
were	O
higher	O
.	O

In	O
patients	O
seropositive	O
for	O
anti-AchR	O
antibodies	I:C0236516
,	O
the	O
frequencies	O
of	O
HLA	O
-	O
B*50	O
and	O
C*05	B:C0062856
were	O
higher	O
.	O

HLA	B:C0062856
-	I:C0062856
C*05	I:C0062856
,	O
DRB1*01	O
,	O
and	O
DRB1	O
*	I:C1699878
11	I:C1699878
were	O
higher	O
in	O
patients	O
with	O
ocular	O
MG	I:C0751340
.	O

HLA	O
-	I:C0062856
C*05	I:C0062856
,	O
DRB1*01	B:C1566853
,	O
and	O
DRB1	O
*	I:C1699878
11	I:C1699878
were	O
higher	O
in	O
patients	O
with	O
ocular	O
MG	I:C0751340
.	O

HLA	O
-	I:C0062856
C*05	I:C0062856
,	O
DRB1*01	O
,	O
and	O
DRB1	B:C1699878
*	I:C1699878
11	I:C1699878
were	O
higher	O
in	O
patients	O
with	O
ocular	O
MG	I:C0751340
.	O

HLA	O
-	I:C0062856
C*05	I:C0062856
,	O
DRB1*01	O
,	O
and	O
DRB1	O
*	I:C1699878
11	I:C1699878
were	O
higher	O
in	O
patients	O
with	O
ocular	B:C0751340
MG	I:C0751340
.	O

In	O
addition	O
,	O
HLA	B:C0019728
-	I:C0019728
A*01	I:C0019728
,	O
A	O
*31	I:C0121978
,	O
B*08	O
,	O
and	O
DRB1	O
*	I:C0122040
14	I:C0122040
were	O
higher	O
among	O
patients	O
with	O
thymic	O
hyperplasia	I:C0040115
,	O
whereas	O
DQB1*03	O
was	O
lower	O
.	O

In	O
addition	O
,	O
HLA	O
-	I:C0019728
A*01	I:C0019728
,	O
A	B:C0121978
*31	I:C0121978
,	O
B*08	O
,	O
and	O
DRB1	O
*	I:C0122040
14	I:C0122040
were	O
higher	O
among	O
patients	O
with	O
thymic	O
hyperplasia	I:C0040115
,	O
whereas	O
DQB1*03	O
was	O
lower	O
.	O

In	O
addition	O
,	O
HLA	O
-	I:C0019728
A*01	I:C0019728
,	O
A	O
*31	I:C0121978
,	O
B*08	B:C0019737
,	O
and	O
DRB1	O
*	I:C0122040
14	I:C0122040
were	O
higher	O
among	O
patients	O
with	O
thymic	O
hyperplasia	I:C0040115
,	O
whereas	O
DQB1*03	O
was	O
lower	O
.	O

In	O
addition	O
,	O
HLA	O
-	I:C0019728
A*01	I:C0019728
,	O
A	O
*31	I:C0121978
,	O
B*08	O
,	O
and	O
DRB1	B:C0122040
*	I:C0122040
14	I:C0122040
were	O
higher	O
among	O
patients	O
with	O
thymic	O
hyperplasia	I:C0040115
,	O
whereas	O
DQB1*03	O
was	O
lower	O
.	O

In	O
addition	O
,	O
HLA	O
-	I:C0019728
A*01	I:C0019728
,	O
A	O
*31	I:C0121978
,	O
B*08	O
,	O
and	O
DRB1	O
*	I:C0122040
14	I:C0122040
were	O
higher	O
among	O
patients	O
with	O
thymic	B:C0040115
hyperplasia	I:C0040115
,	O
whereas	O
DQB1*03	O
was	O
lower	O
.	O

In	O
addition	O
,	O
HLA	O
-	I:C0019728
A*01	I:C0019728
,	O
A	O
*31	I:C0121978
,	O
B*08	O
,	O
and	O
DRB1	O
*	I:C0122040
14	I:C0122040
were	O
higher	O
among	O
patients	O
with	O
thymic	O
hyperplasia	I:C0040115
,	O
whereas	O
DQB1*03	B:C0122020
was	O
lower	O
.	O

No	O
allele	B:C0002085
association	O
was	O
found	O
among	O
patients	O
with	O
thymoma	O
.	O

No	O
allele	O
association	O
was	O
found	O
among	O
patients	O
with	O
thymoma	B:C0040100
.	O

Strikingly	O
,	O
patients	O
with	O
generalized	B:C0751339
MG	I:C0751339
who	O
had	O
pure	O
ocular	I:C0751340
symptoms	O
at	O
disease	O
onset	O
had	O
significantly	O
increased	O
HLA	O
-	O
B	O
*	O
50	O
compared	O
to	O
the	O
controls	O
(	O
corrected	O
p	O
<	O
0.001	O
,	O
OR	O
=	O
9.92	O
;	O
95	O
%	O
CI	O
3.05	O
-	O
32.22	O
)	O
.	O

Strikingly	O
,	O
patients	O
with	O
generalized	O
MG	I:C0751339
who	O
had	O
pure	B:C0751340
ocular	I:C0751340
symptoms	O
at	O
disease	O
onset	O
had	O
significantly	O
increased	O
HLA	O
-	O
B	O
*	O
50	O
compared	O
to	O
the	O
controls	O
(	O
corrected	O
p	O
<	O
0.001	O
,	O
OR	O
=	O
9.92	O
;	O
95	O
%	O
CI	O
3.05	O
-	O
32.22	O
)	O
.	O

Strikingly	O
,	O
patients	O
with	O
generalized	O
MG	I:C0751339
who	O
had	O
pure	O
ocular	I:C0751340
symptoms	B:C1457887
at	O
disease	O
onset	O
had	O
significantly	O
increased	O
HLA	O
-	O
B	O
*	O
50	O
compared	O
to	O
the	O
controls	O
(	O
corrected	O
p	O
<	O
0.001	O
,	O
OR	O
=	O
9.92	O
;	O
95	O
%	O
CI	O
3.05	O
-	O
32.22	O
)	O
.	O

The	O
HLA	B:C0002085
-	I:C0002085
B*50	I:C0002085
allele	I:C0002085
was	O
associated	O
with	O
conversion	O
to	O
generalized	O
disease	I:C0849867
in	O
patients	O
with	O
pure	O
ocular	I:C0751340
symptoms	O
at	O
disease	O
onset	O
.	O

The	O
HLA	O
-	I:C0002085
B*50	I:C0002085
allele	I:C0002085
was	O
associated	O
with	O
conversion	O
to	O
generalized	B:C0849867
disease	I:C0849867
in	O
patients	O
with	O
pure	O
ocular	I:C0751340
symptoms	O
at	O
disease	O
onset	O
.	O

The	O
HLA	O
-	I:C0002085
B*50	I:C0002085
allele	I:C0002085
was	O
associated	O
with	O
conversion	O
to	O
generalized	O
disease	I:C0849867
in	O
patients	O
with	O
pure	B:C0751340
ocular	I:C0751340
symptoms	O
at	O
disease	O
onset	O
.	O

The	O
HLA	O
-	I:C0002085
B*50	I:C0002085
allele	I:C0002085
was	O
associated	O
with	O
conversion	O
to	O
generalized	O
disease	I:C0849867
in	O
patients	O
with	O
pure	O
ocular	I:C0751340
symptoms	B:C1457887
at	O
disease	O
onset	O
.	O

This	O
finding	O
could	O
extend	O
our	O
understanding	O
of	O
the	O
complex	O
interactions	O
between	O
the	O
pathogenesis	B:C0699748
of	O
myasthenia	O
gravis	I:C0026896
and	O
genetic	O
heritage	O
.	O

This	O
finding	O
could	O
extend	O
our	O
understanding	O
of	O
the	O
complex	O
interactions	O
between	O
the	O
pathogenesis	O
of	O
myasthenia	B:C0026896
gravis	I:C0026896
and	O
genetic	O
heritage	O
.	O

